A Phase II Study of Bevacizumab (Avastin&reg;) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy

A Phase II Study of Bevacizumab (Avastin&reg;) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy - ADOPT study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007123

Enrollment

Registered

2012-02-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-sq NSCLC with previously treated

Interventions

Bevasizumab + Pemetrexed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Pathologically or cytplogically confirmed non-small cell lung cancer. Patients with clinical stage IIIB/IV or postoperative recurrence, and unsuitable for radiotherapy. (2) Previously treated (3) Patients who has measurable by RECIST(ver 1.1)criteria. (4) performance status of 0-2 (5) Age of 20 years or older (6) Adequate organ functions (7) Life expectancy more than 90 days (8) Written informed consent

Exclusion criteria

Exclusion criteria: (1) Previously untreated with platinum doublet (2) transfusion or G-CSF within 2weeks prior to enrollment (3) Severe renal function disorder, 2+ or higher proteinuria within 2 weeks prior to enrollment (4) History of severe drug allergy (5) History of active double cancer within 5 years (6) History of active severe infections (7) Patients who have fever of over 38 degrees (8) Continuous administration of steroid drug (9) severe cardiac disease (10) History of thromboembolism or severe pulmonary disease (11) History of GI bleeding , ileus, GI ulceration (12) massive pleural or pericardial effusion, ascites (13) Symptomatic brain metastases (14) Uncontrollable hypertension or diabetes mellitus (15) Uncontrollable diarrhea (16) Wound of unrecovery (17) Traumatic fracture of unrecovery (18) bleeding diathesis or receiving anticoagulant drug(except Aspirin under 324mg/day) (19) History of pregnancy or lactation (20) Evaluated to be ineligible by a physician for other reasons

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
disease control rate,overall survival, and safety	—

Countries

Japan

Contacts

Public ContactKazunori Fujitaka

Hiroshima University Hospital Respiratory medicine

81-082-257-5195

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

A Phase II Study of Bevacizumab (Avastin&amp;reg;) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy